Lutetium (177Lu) vipivotide tetraxetan

镥[177Lu] 特昔维匹肽

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameLutetium (177Lu) vipivotide tetraxetan
Drug Alias Name177-Lutetium-PSMA-617（Endocyte）镥[¹⁷⁷Lu]特昔维匹肽177-LU-PSMA-617（Endocyte）Lutetium (177Lu) vipivotide tetraxetan (Advanced Accelerator Applications)lutetium Lu 177 vipivotide tetraxetan +[16] 
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsCytopeniaThrombocytopeniaAnemia +[13] 
Global Approved IndicationsProstatic Neoplasms, Castration-Resistant
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date2022/03/23
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRadiomedix Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma KkAdvanced Accelerator Applications International SaDana-Farber Cancer Institute +[17] 
Inactive CompaniesAdvanced Accelerator Applications Usa IncRadboud University Medical CenterThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsNeoplasm MetastasisKidney NeoplasmsProstatic Neoplasms, Castration-Resistant +[9] 
Inactive IndicationsCytopeniaThrombocytopeniaAnemia +[4] 

Other Information

ATC CodeN/A
Related LinksN/A